Securitisation
United States
13 March 2025
A&O Shearman demonstrates capabilities in both life sciences and tech patents and has a strong track record in all major litigation venues. The team is particularly strong on Hatch-Waxman on both the brand and generic side. The team is led by New York’s Elizabeth Holland, a first-chair trial lawyer sought after by pharma, biotech and medical device companies. In Boston, John Bennett specializes in Hatch-Waxman and BPCIA cases. William James, in Washington DC, is another key Hatch-Waxman specialist who also focuses on IPR and appellate proceedings.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘The A&O Shearman team is nothing but excellent. Very knowledgeable about our industry and the law, always available, providing practical no-nonsense advice.’
‘Tom (Thomas) Makin is outstanding. He is always available, excellent understanding of our industry, situation and how to navigate.’
Key clients
- University of Pennsylvania
- Alcon
- AbbVie
- Esperion
- Genmab A/S
- Vantage Specialty Chemicals
- Nichia
- Novartis
- Olympus Corporation
- GE Healthcare
Work highlights
Advised University of Pennsylvania in a patent infringement litigation asserting its U.S. Patent No. 7,625,558 (methods of treating cancer tumors) against Genentech's multi-billion dollar products Herceptin, Perjeta, and Phesgo.
Advised Alcon in the District of Delaware against Padagis Israel Pharmaceuticals Ltd., Padgis US LLC, and Padagis LLC (“Padagis”).
Advised AbbVie Inc. and Allergan Pharmaceuticals International Ltd. (“AbbVie”) as lead counsel in Hatch-Waxman patent infringement matters against defendants Fresenius Kabi, Apotex, and Qilu Pharmaceuticals pending in the District of New Jersey and the Northern District of Illinois.
Lawyers
Practice head
Elizabeth Holland
Other key lawyers
John Bennett; William James; Thomas Makin